Fibrodysplasia ossificans progressiva |
| |
Authors: | Kaplan Frederick S Le Merrer Martine Glaser David L Pignolo Robert J Goldsby Robert E Kitterman Joseph A Groppe Jay Shore Eileen M |
| |
Affiliation: | Departments of Orthopedic Surgery & Medicine, The University of Pennsylvania School of Medicine, c/o Hospital of The University of Pennsylvania, Philadelphia, PA, USA. frederick.kaplan@uphs.upenn.edu |
| |
Abstract: | Fibrodysplasia ossificans progressiva (FOP), a rare and disabling genetic condition of congenital skeletal malformations and progressive heterotopic ossification (HO), is the most catastrophic disorder of HO in humans. Episodic disease flare-ups are precipitated by soft tissue injury, and immobility is cumulative. Recently, a recurrent mutation in activin receptor IA/activin-like kinase 2 (ACVR1/ALK2), a bone morphogenetic protein (BMP) type I receptor, was reported in all sporadic and familial cases of classic FOP, making this one of the most highly specific disease-causing mutations in the human genome. The discovery of the FOP gene establishes a critical milestone in understanding FOP, reveals a highly conserved target for drug development in the transforming growth factor (TGF)-beta/BMP signalling pathway, and compels therapeutic approaches for the development of small molecule signal transduction inhibitors for ACVR1/ALK2. Present management involves early diagnosis, assiduous avoidance of iatrogenic harm, and symptomatic amelioration of painful flare-ups. Effective therapies for FOP, and possibly for other common conditions of HO, may potentially be based on future interventions that block ACVR1/ALK2 signalling. |
| |
Keywords: | fibrodysplasia ossificans progressiva (FOP) heterotopic ossification bone morphogenetic protein BMP ACVR1 ALK2 |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|